Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)
Progenics Pharmaceutical is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra TM , an ultra-orphan radiotherapy candidate also in phase 2 under an SPA. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan.
Company Website: http://www.progenics.com/
Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) Stock Message Board
2952 | Sponsor | 03/29/2024 5:46:12 AM | |
5 | Latest Progenics Pharmaceuticals Inc (PGNX) | Stock_Tracker | 03/13/2014 12:32:46 PM |
4 | PGNX Stock Charts Last: -0.22 Saturday, March 1, | chartguy89 | 03/01/2014 9:11:10 PM |
3 | PGNX Stock Charts Last: +0.15 Friday, February | chartguy89 | 02/28/2014 3:12:13 AM |
2 | $PGNX higher highs $6.76 Shares Outstanding | PoemStone | 01/14/2014 8:43:50 PM |
1 | Wow first post. I believe this is gonna fly in | Koocynnhoj | 03/09/2013 1:48:10 AM |